We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Oral Contraceptives Impact Quality of Life

By HospiMedica International staff writers
Posted on 03 May 2017
A new study demonstrates a statistically significant reduction in general wellbeing of women using oral contraceptives.

Researchers at Karolinska Institutet, Karolinska University Hospital, and other institutions conducted a double-blind, placebo-controlled trial involving 340 healthy women (18-35 years of age) who were randomized to a combined oral contraceptive (150 μg levonorgestrel and 30 μg ethinylestradiol) or placebo for three months of treatment. More...
Primary outcome measures included global score of the Psychological General Well-Being Index (PGWBI) and the Beck Depression Inventory (BDI).

In all, 332 women completed data collection at follow-up evaluation. The results showed that the oral contraceptive treatment significantly decreased general wellbeing, compared with placebo. In addition, several PGWBI dimensions were decreased compared with placebo, including positive wellbeing, self-control, and vitality. The effect of oral contraceptives on depressive symptoms and on the PGWBI “depressed mood” dimension were not statistically significant. The study was published on April 19, 2017, in Fertility and Sterility.

“Despite the fact that an estimated 100 million women around the world use contraceptive pills, we know surprisingly little today about the pill’s effect on women’s health,” said lead author Professor Angelica Lindén Hirschberg, MD, of Karolinska Institutet. “The scientific base is very limited as regards the contraceptive pill’s effect on quality of life and depression, and there is a great need for randomized studies where it is compared with placebos.”

The combined oral contraceptive pill, colloquially known as "the pill", is a birth control method that includes a combination of an estrogen and a progestogen. When taken per-os daily, these pills inhibit female fertility (with reversibility). Pills containing ethinylestradiol and levonorgestrel are the first choice of combined oral contraceptives in Sweden and many other countries, as they are considered to entail the least risk of thrombosis among all combined contraceptive pills.


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Electric Bed
DIXION Intensive Care Bed
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.